June 19, 2014 -WESTIMINSTER, Colo.— Surefire Medical, Inc., a commercial stage medical device company developing innovative devices for minimally invasive, direct-to-tumor interventional procedures, today announced that CEO and President James E. Chomas has been selected as a finalist for the Ernst & Young Entrepreneur Of The Year™ 2014 Award in the Mountain Desert region.

The awards program recognizes entrepreneurs who demonstrate excellence and extraordinary success in areas such as innovation, financial performance and personal commitment to their businesses and communities.

Under Chomas’s leadership, Surefire Medical has raised $26 million from investors and recruited seasoned executives, researchers and sales/marketing teams as the company continues its growth trajectory.

“Being selected as a finalist in this prestigious award program is truly a reflection of the dedication of the entire Surefire Medical team to developing novel, minimally invasive approaches for treating some of the 80 percent of liver cancer patients with inoperable tumors,” Chomas said. “A growing body of clinical research shows the cost-effectiveness and potential clinical benefits of the Surefire technology, including increased penetration of therapeutics into tumors and precise targeting that can protect healthy tissue from harm, making it possible to bring treatment – and hope – to more people worldwide.”

Liver cancer is the third most common cause of cancer deaths worldwide, with 2.2 million cases. Rising hepatitis B and C rates contribute to growing incidence, as do high metastasis rates, most notably from colorectal, breast, skin and kidney cancers.

Chomas was selected as a finalist from nearly 100 nominations in three states by a panel of independent judges. Award winners will be announced on June 26, 2014. The winners are eligible for consideration for the EY Entrepreneur of the Year national program.

About Surefire Medical

Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative devices for the interventional radiology and interventional oncology markets. Surefire’s infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue. The Surefire Infusion Systems have received regulatory approval in the U.S., Europe, Canada, Australia, New Zealand and Taiwan. www.surefiremedical.com

About EY Entrepreneur Of The Year™

EY Entrepreneur Of The YearTM is the world’s most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries.


Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.